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Summary We have performed an analysis of ras, c-myc, c-myb, c-erbBl and c-erbB2 onocogenes in 100
surgical samples of human breast carcinomas. No point mutations have been detected at the 12th codon of c-
Ha-ras and c-Ki-ras in 40 and 65 breast cancer DNAs, respectively. One out of 65 samples showed a 50-fold
amplification of c-Ha-ras that, however, was not overexpressed. Alterations in the structure of c-myc, c-myb
c-erbBl and c-erbB2 oncogenes were sporadically observed. In 20 tumour samples, the study of expression of
a series of oncogenes revealed that c-Ha-ras was the predominantly transcribed gene among the ras gene
family whereas c-fos appeared the most constantly and significantly expressed nuclear oncogene.
Genetic changes which contribute to the onset and progres-
sion of cancer are still largely obscure in spite of the fact
that the activation of certain cellular proto-oncogenes has
frequently been implicated in most types of human tumours.
In particular, mutated alleles of ras family genes have been
found in about 15% of the most common forms of human
cancers (Pulciani et al., 1982) and several proto-oncogenes
have been found to be amplified in a variety of tumour cell
lines and primary tumours (Alitalo et al., 1983; Escot et al.,
1986; Kozbor & Croce, 1984; Little et al., 1983; Yokota et
al., 1986). In breast cancer, the only report of a DNA
transforming activity was provided by Kraus et al. (1984)
who showed the activation of the c-Ha-ras oncogene in a
carcinosarcoma cell line. Amplifications and/or alterations of
c-myc and c-myb were reported in both cell lines and fresh
samples of breast carcinomas (Escot et al., 1986; Kozbor &
Croce, 1984; Yokota et al., 1986). A cellular gene related to
v-erbB, c-erbB2/neu, was also found amplified in breast
cancer and the amplification was suggested to be of
prognostic value (Slamon et al., 1987). Finally. Theillet et al.
(1986) detected a loss of c-Ha-ras alleles in a significant
number of breast cancer DNAs and suggested a relation to
aggressively growing tumours.
In this report we present the results of the analysis of the
genomic organisation of several oncogenes in 100 cases of
human breast carcinomas and of a study of oncogene
expression in 20 of them.
Patients and methods
Case material
Tumour specimens from 83 primary breast carcinomas and
17 lymph node metastases were collected from an unselected
series of 100 patients observed at our Institute. The tumours
were classified following the WHO Histological Typing of
Breast Tumours (1981) as: 54 infiltrating ductal carcinomas,
22 infiltrating lobular carcinomas, 17 mixed, infiltrating
ductal and lobular carcinomas, 3 mixed, infiltrating ductal
and mucinous carcinomas, 2 medullary carcinomas and 2
mixed, infiltrating ductal and papillary carcinomas. The
tumour specimens contained at least 50% of malignant cells,
evaluated microscopically.
When possible, the corresponding peripheral blood
leukocytes (PBL) were collected.
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DNA isolation, Southern blot and hybridization
High molecular weight DNA was prepared from tumour
tissues and from PBL according to standardized procedure.
The DNA extracted was subjected to digestion with ap-
propriate endonucleases, electrophoresed in agarose and
transferred on Gene Screen Plus nylon membrane (New
England Nuclear, Firenze, Italy), according to previously
established conditions (Southern, 1975).
The filters were hybridized with 32P labelled probes for
18 h and washed extensively under stringent conditions. After
being dried, the filters were exposed at -70°C with Trimax
3M XR films with intensifying screens for varying periods of
time.
RNA isolation, poly(A)+ selection, Northern and slot blot
analysis
Cesium chloride gradient centrifugation was used to isolate
the RNA from solubilized tissue samples and from PBL
according to previously described procedure (Raymond &
Shore, 1979). Poly(A+) RNA was obtained by passing the
total RNA extracted on Hybond TM-mAP paper
(Amersham). Poly(A+) RNA was electrophoresed in 1%
agarose containing formaldehyde as previously described
(Southern, 1975). Total RNA was used for slot blot analysis
as was previously described by Slamon et al. (1984). The
level of hypoxanthine phosphoribosyltransferase expression
was used to normalize the relative amount of RNA in the
different tissue samples. Autoradiographic scans were per-
formed with a laser densitometric scanner (LKB).
Probes
The human c-Ha-ras (pbcNl) Bam HI 6.6kb fragment and
c-Ki-ras (pESl9) Sau 3A fragment were given by Dr M.
Barbacid (Pulciani et al., 1982; Santos et al., 1984). The
pKyl probe detecting RFLP at c-Ha-ras 12th codon, was
provided by Dr M. Kraus. The c-myc probe (pRyc 7.4)
containing the entire c-myc 3rd exon and part of the 2nd
exon (Marcu et al., 1983) and c-myb representing a 1.2kb
PstI DNA fragment from K562 cell line (Pelicci et al., 1984)
were both provided by Dr C. Croce. c-erbBl/EGF-R gene
probe EcoRI 770bp fragment was provided by Dr M.
Waterfield (Libermann et al., 1985). c-erbB2/neu gene was
detected with the SacI-EcoRI 1.9kb fragment from v-erbB
provided by Dr B. Vennstr6m (Damm et al., 1987). The c-
fos probe was provided by Dr I. Verma and represented an
EcoRI 9.0kb DNA fragment of the human pc-fos plasmid
(Miller et al., 1984). The c-mos (LE392) plasmid was a
2.75 kb EcoRI fragment given by Dr G.F. Vande Woude
(Oskarsson et al., 1980).
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Results
Analysis of the structure of the ras genes
Mutation of the 12th codon of c-Ha-ras and c-Ki-ras The
DNAs of 40 human carcinomas were digested with an excess
of Hpa II and MspI restriction enzymes and analysed in
Southern blot using the 411 bp MspI DNA fragment (pKyl)
derived from the first exon of the c-Ha-ras oncogene (Figure
IA) (Kraus et al., 1984). None of them showed evidence of
an activating mutation at the 12th codon of the c-Ha-ras
oncogene. As shown in Figure 1B, 4 representative tumour
DNAs and a DNA from PBL hybridized as a single 355bp
fragment whereas the mutated c-Ha-ras oncogene from T24
bladder carcinoma cell line yielded a single 411 bp DNA
fragment.
Using a similar approach we have analysed 65 tumour
samples for c-Ki-ras activation. Using pES19 as probe, a
point mutation at the 34th or 35th position of the first exon
of c-Ki-ras would generate a recognition site for the enzymes
Sacd and Fnu4HI, respectively (Santos et al., 1984). No
base substitutions were observed in any of the samples
analysed (data not shown).
Amplification and rearrangement ofc-Ha-ras, c-Ki-ras and N-
ras proto-oncogenes We have analyzed the DNAs of 65
breast carcinomas for structural amplification and/or re-
arrangement of ras proto-oncogenes. c-Ha-ras was found
unaltered in all tumour samples but one that showed a 50-
fold amplification of the gene. The amplification was seen
only in the tumour DNA and not in the DNA extracted from
PBL of the same patient (Figure 2). None of the 65 samples
showed any alterations of c-Ki-ras and N-ras genes.
Loss of c-Ha-ras allele Using a TaqI c-Ha-ras poly-
morphism (Pierotti et al., 1986) the reported loss ofa c-Ha-ras
allele (Theillet et al., 1986) was evaluated. Southern blot
analysis of DNA extracted from 29 primary tumours and
matching PBL and from the tumour specimens of 6 patients
who were heterozygous for the c-Ha-ras locus, revealed the
loss of one allele in 3 cases (8.6%), as shown in Figure 3.
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Figure 2 c-Ha-ras gene amplification in one breast carcinoma.
20pg DNA were digested with BamHI and hydridized with













Figure 3 Loss of c-Ha-ras allele in three breast carcinomas.
20,ug DNA were restricted with TaqI and hydridized with
pbcNI. Tumours (lanes a, c, e) and homologous PBL (lanes b, d,
f).
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Analysis of the structure of c-myc, c-myb, c-erbBl and
c-erbB2 protooncogenes
The DNAs of 45 breast carcinomas were digested with
EcoRI and hybridized with the c-myc specific probe. A single
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Figure 1 (A) The restriction map of the 411 bp pkyl probe
utilized to reveal mutations at the 12th codon of the first exon of
c-Ha-ras; (B) 60pg DNA of 4 breast carcinomas (lanes a-d), of
T24 bladder carcinoma cell line (lane e), and of normal PBL
(lane f) were extensively digested with HpaII and MspI,
electrophoresed, and transferred on Z-probe filter. Hybridization
was performed overnight using pKyl probe nick-translated to a
specific activity of 1 x 109.
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Figure 4 Amplification of c-myc in one breast carcinoma. DNA
was digested with EcoRI and hybridized with pRyc 7.4. Lane (a)
HL60 DNA 20jug. Lanes (b-d) breast carcinoma DNA, 50pg (b),
20,ug (c), lOpg (d). Lane (e) homologous PBL DNA 20yg.
However, 2 DNAs contained a 2- and a 18-fold amplifi-
cation of the gene, respectively. The latter DNA was
analysed at different concentrations as shown in Figure 4
and compared to the DNA of HL-60 and of the PBL of the
same patient.
The DNAs of 43 tumour samples had the normal c-myb
germ line Hind III fragments of 7.4 and 4.1 kb. Two samples
contained an extra 8.3 kb band, which appears to have
substituted the normal 4.1 kb fragment (Figure 5).
We analyzed 20 breast carcinoma DNAs for c-erbBI/
EGF-R amplification and/or rearrangement and found that
one case contained rearranged bands. The rearrangement
was observed with EcoRI that yielded a 4.2kb band in the
DNA prepared from the tumour and not in the DNA
extracted from PBL of the same patient (Figure 6 panel 1).
The rearrangement was confirmed using Bgl II (panel 2) and
Bam HI (panel 3) restriction enzymes.
Using as a probe a fragment of v-erbB oncogene similar to
that described by King et al. (1985) that allows the detection
of c-erbB2/neu related sequences, we examined the DNA
ls - - wS
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Figure 5 Rearrangement of c-myb in two breast carcinomas
DNA. 20 jg DNA were restricted with Hind III and hybridized
with p c-myb. Two breast carcinomas had the normal germ line










Figure 6 Rearrangement of c-erbBl/EGF-R gene in one breast
carcinoma. 20pg DNA were digested with EcoRI (panel 1), Bgl
II (panel 2) and Bam Hl (panel 3) and hybridized with the
cytoplasmic domain of the EGF-R. Tumour (lane a);




Figure 7 Amplification of c-erbB2/neu in a breast carcinoma
DNA. 20 ug DNA were digested with EcoRI and hybridized
(30% formamide) with SacI-EcoRI v-erbB fragment at low
stringency. A 6.6kb band was amplified in the tumour DNA
lane 2 and not in the DNA from the patient's PBL (lane 1) nor
in placenta DNA (lane 3).
from tumour and PBL of 25 patients. An amplification of
c-erbB2/neu gene was observed in 2 cases, one of which is
shown in Figure 7 (lane 2).
Oncogene expression
The level of expression of 8 oncogenes was determined in 20
RNAs extracted from primary breast carcinoma specimens
(Table I). The RNA levels were established from slot blot
Figure 8 Northern analysis of the expression of c-Ha-ras in
human breast carcinoma patients. 5jig poly(A+) RNA were
loaded on 1% formaldehyde agarose gel. The filter obtained was
hybridized with pbcNI probe. Lanes (a to h) tumours, lane (i)
normal PBL. Lane (f) refers to the case with c-Ha-ras gene
amplification (Figure 2).
analysis and represent only relative values in that the tumour
tissue samples contained stromal cells and variable amounts
of infiltrating macrophages and other inflammatory cells
besides malignant cells. A sample was scored positive for a
given oncogene when its expression was at least 2-fold higher
than the level found in a pool of control PBL. We as well as
others (Slamon et al., 1984) have used PBL as control
material because of the difficulty in obtaining normal breast
tissue. The expression of c-fos was scored positive in 75% of
the tested samples. Among the ras gene family, c-Ha-ras was
significantly transcribed in 65% of the cases whereas c-Ki-
ras and N-ras were positively expressed in 30% and 15% of
the samples, respectively, and only one of the 20 samples
showed simultaneous expression of the three ras genes. C-
myc, c-myb, c-mos and EGF-R were also found expressed
with a frequency ranging from 20 to 30%.
As shown in Figure 8, a Northern blot analysis with c-Ha-
ras probe and Poly(A+) mRNAs of 8 cases confirmed the
expression of c-Ha-ras of the samples scored positive in the
slot blot assay. It should be noted that the mRNA in lane f
of Figure 8 derives from the tumour that displayed a 50-fold
amplification of c-Ha-ras gene that clearly was not over-ex-
pressed.
The analysis of pathological parameters showed no
significant correlations between the size of the tumours and
the number of positive lymph nodes and the level of
transcription of c-Ha-ras and of c-fos (Table I).
Discussion
The purpose of our work was to analyze the genic structure
of the ras oncogenes and of other oncogenes most frequently
found altered in fresh human tumours, in order to find
possible molecular alterations which could be correlated with
breast cancer.
Using an RFLP approach (Kraus et al., 1984; Santos et
al., 1984), we analyzed point mutations affecting the 12th
codon of the c-Ha-ras and c-Ki-ras oncogenes in 40 and 65
cases, respectively, and in none of them were base substi-
tutions at these sites identified. Due to lack of appropriate
probes, we were unable to analyse point mutations affecting
other codons of c-Ha-ras and c-Ki-ras or mutations of
N-ras; however, most of the cases were also analyzed in a
standard transfection assay and found negative (S. Sukumar
and M. Barbacid, personal communication). This negative
observation is in keeping with the fact that, so far, only one
report has shown an activation, by point mutation, of the
c-Ha-ras oncogene in a breast carcinosarcma cell line whose
DNA displayed transforming activity in the NIH-3T3 trans-
fection assay (Kraus et al., 1984), whereas a large study on
more than 100 samples was negative (Theillet et al., 1986).
This suggests that ras oncogene activation must occur very
infrequently, if at all, in human breast cancer. Also gene
amplification does not seem to play a role since we found a
50-fold c-Ha-ras gene amplification in only one tumour
which, moreover, did not demonstrate overexpression of the
gene.ONCOGENE EXPRESSION IN BREAST CANCER 467
Table I Oncogene expression in 20 breast carcinomas'
Tumour Number of
Case diameter positive EGFR
number (cm) lymph nodes c-Ha-ras c-Ki-ras N-ras c-myc c-myb c-mos c-fos (c erbB)
1 20.0 8 +3 1 1 +2 1 1 +3 1
2b 5.0 8 +2 1 1 1 1 1 +4 +2
3 na na 1 1 0 1 1 1 +2 1
4 3.9 2 +4 +2 1 1 1 1 +2 1
5 3.5 1 +4 1 1 1 1 1 1 1
6 10.0 8 +4 1 1 1 +2 1 +4 +2
7 2.5 1 +4 1 1 1 +2 +2 +4 1
8 3.0 5 +4 +2 +2 +2 1 +2 +2 1
9 8.0 na +5 +2 1 1 +2 +3 +3 1
10 2.3 0 +4 +2 1 +3 1 1 +2 1
11 4.5 7 1 1 1 1 +3 1 +3 +2
12 5.5 6 +4 1 +2 +3 1 +2 +3 1
13 3.0 0 0 +2 1 1 1 1 +3 1
14 4.0 5 +4 1 1 1 +2 +2 +3 1
15 4.0 5 +4 1 1 1 1 +2 +4 +2
16 0.4 4 0 1 +2 1 1 1 +3 1
17 2.5 0 1 1 1 1 1 1 0 1
18 4.0 5 +5 1 1 1 1 1 0 1
19 2.2 3 1 +3 1 1 1 1 1 1
20 2.5 10 1 1 1 1 1 1 1 1
Percentages of cases expressing the oncogenes at least 2 times above control
65% 30% 15% 20% 25% 30% 75% 20%
ao_I no or background expression; +n times RNA above the level of a pool of control PBL; bthis case displays a 50-fold
amplification of Ha-ras; na=not available.
The c-Ha-ras protooncogene is polymorphic in human
DNA as a result of the variable tandem reiteration of a 28-
base pair sequence (VTR) adjacent to the c-Ha-ras gene
(Goldfrab et al., 1982). Theillet et al., (1986) analysing c-Ha-
ras polymorphism in normal and breast cancer DNAs
observed a loss of c-Ha-ras alleles in 27% of 51 breast
carcinomas diagnosed as highly aggressive infiltrating ductal
carcinoma. The loss of heterozygosity for chromosome 11
loci appears to have a significant correlation with tumours
which have lost hormonal dependency, are in grade III and
have metastasized distally (Ali et al., 1987). In 35 breast
cancer patients for which matching PBL were available or
the tumour tissue displayed heterozygosity, we found that
only 8.6% had lost one c-Ha-ras locus. Consequently, it
appears that in our sampling the loss of c-Ha-ras alleles is
related to stochastic events as was suggested by other
investigators studying this phenomenon in human
melanomas (Dracopoli et al., 1985).
As for the expression of ras genes, we found that c-Ha-ras
was the most constantly transcribed gene, in agreement with
other reports (Lidereau et al., 1986; Theillet et al., 1986) but
in contrast with the results of Whittaker et al. (1986) who
reported on the absence of c-Ha-ras transcripts both in
normal and breast carcinoma samples. The discrepancy may
be due to differences in the probes used.
We attempted to correlate the expression of ras oncogene
with pathological data and observed no significant cor-
relations.
Alterations of c-myc and c-myb have been suggested to
occur most frequently in highly aggressive ductal and
metastatic breast carcinomas (Escot et al., 1986; Kozbor &
Croce, 1984; Yokota et al., 1986). Our study detected c-myc
amplification in 2 out of 45 cases and c-myb rearrangement
in 2 out 43, and did not allow any clinical correlation. The
discrepancy between our c-myc data and those reported by
Escot et al. (1986) may be due to the difference in histo-
pathological grading and age of the patients under analysis.
Escot found c-myc amplification mainly in patients over 50
years whereas our patients averaged 42 years. Recently, it
has been shown that the number of metastatic lymph nodes
in breast cancer was correlated with the amplification of the
c-erbB2/neu gene, which therefore seems to be a prognostic
indicator (Slamon et al., 1987). We found an amplification
of the c-erbB2/neu gene in only 2 of our unselected series of
25 breast carcinoma patients. Rearrangement of c-erbBl/
EGF-R gene occurred in only one case. As for the expres-
sion of the oncogenes whose product has been localized in
the nucleus, only c-fos resulted consistently expressed and
this may be due to infiltrating macrophages, which can
contribute to c-fos expression in solid breast tumours
(Gottlinger et al., 1985).
In conclusion, our data indicate that none of the presently
investigated oncogenes appears to play a key role in the
development of breast carcinomas. We stress therefore the
need to develop new approaches in order to identify genes
involved in the initial events of cellular transformation in
this highly frequent human neoplasia.
This work was supported by a contract from Ministero della Sanita,
Roma, and by Associazione Italiana Ricerca Cancro. The authors
acknowledge Mr Mario Azzini for his technical assistance and Mrs
Giovanna Raineri for typing the manuscript.
References
ALI, I.U. LIDEREAU, R. THEILLET, C. & CALLAHAN, R. (1987).
Reduction to homozygosity of gene on chromosome 11 in
human breast neoplasia. Science, 238, 185.
ALITALO, K., SCHWAB, M., LIN, C.C., VARMUS, H.E. & BISHOP, J.M.
(1983). Homogeneously staining chromosomal regions contain
amplified copies of abundantly expressed cellular oncogene (c-
myc) in malignant neuroendocrine cells from a human colon
carcinoma. Proc. Natl Acad. Sci. USA, 80, 1707.
DAMM, K., BEUG, H., GRAF, T. & VENNSTROM, B. (1987). A single
point mutation in erbA restore the erythroid transforming
potential of a mutant avian erythroblastosis virus (AEV)
defective in both erbA and erbB oncogenes. EMBO J., 6, 375.
DRACOPOLI, N.C., HOUGHTON, A.N. & OLD, L.S. (1985). Loss of
polymorphic restriction fragments in malignant melanoma:
Implications for tumour heterogeneity. Proc. Natl Acad. Sci.
USA, 82, 1470.
ESCOT, C., THEILLET, C., LIDEREAU, R. & 4 others (1986). Genetic
alteration of the c-myc protooncogene (MYC) in human primary
breast carcinomas. Proc. Natl Acad. Sci. USA, 83, 4834.
GOTTLINGER, H.G., RIEBER, P., GOKEL, J.M., LOHE, K.J. &
RIETHMULLER, G. (1985). Infiltrating mononuclear cells in
human breast carcinoma: Predominance of T4+ monocytic cells
in the tumour stroma. Int. J. Cancer, 35, 199.468 1. BIUNNO et al.
GOLDFARB, M., SHIMIZU, K., PERUCHO, M. & WIGLER, M. (1982).
Isolation and preliminary characterization of a human
transforming gene from T24 bladder carcinoma cells. Nature,
296, 404.
KING, C.R., KRAUS, M.H. & AARONSON, S.A. (1985). Amplification
of a novel v-erbB-related gene in a human mammary carcinoma.
Science, 229, 974.
KOZBOR, D. & CROCE. C.M. (1984). Amplification of the c-myc
oncogene in one of the five human breast carcinoma cell lines.
Cancer Res., 44, 438.
KRAUS, M.H., YUASA, Y. & AARONSON, S.A. (1984). A position 12-
activated H-ras oncogene in all HS578T mammary carcino-
sarcoma cells but not normal mammary cells of the same patient.
Proc. Natl Acad, Sci. USA, 81, 5384.
KRAUS, M.H., POPESCU, N.C., AMSBAUGH, S.C. & KING, C.R.
(1987). Overexpression of the EGF receptor-related proto-
oncogene erbB-2 in human mammary tumour cell lines by
different molecular mechanisms. EMBO J., 6, 605.
LIBERMANN, T.A., NUSBAUM, H.R., RAZON, N. & 7 others (1985).
Amplification, enhanced expression and possible rearrangement
of EGF receptor gene in primary human brain tumours of glial
origin. Nature, 313, 144.
LIDEREAU, R. ESCOT, C., THEILLET, C. & 4 others (1986). High
frequency of rare alleles of the human c-Ha-ras-1 protooncogene
in breast cancer patients. JNCI, 77, 697.
LITTLE, C.D., NAU, M.M., CARNEY, D.N., GAZDAR, A.F. & MINNA,
J.D. (1983). Amplification and expression ofthe c-myc oncogene in
human lung cancer cell lines. Nature, 306, 194.
MARCU, K.B., HARRIS, L.J., STANTON, L.W., ERIKSON, J., WATT,
R., & CROCE, C.M. (1983). Transcriptionally active c-myc
oncogene is contained with NIARD, a DNA sequence associated
with chromosome translocations in B-cell neoplasia. Proc. Natl
Acad. Sci. USA, 80, 519.
MILLER, A.D., CURRAN, T. & VERMA, I.M. (1984). c-fos protein can
induce cellular transformation: A novel mechanism of activation
of a cellular oncogene. Cell, 36, 51.
OSKARSSON, M., McCLEMENTS, W.L., BLAIR, O.G., MAIZEL, J.V. &
VANDE WOUDE, G.F. (1980). Properties of a normal mouse cell
DNA sequence (sarc) homologous to the src sequence of
Moloney sarcoma virus. Science, 207, 1222.
PELICCI, P.G., LANFRANCONE, L., BRATHWAITE, M.D., WOLMAN,
S.R. & DALLA FAVERA, R. (1984). Amplification of the c-myb
oncogene in a case of human acute myelogenous leukemia.
Science, 224, 1117.
PIEROTTI, M.A., RADICE, P., BIUNNO, I., BORRELLO, M.G.,
CATTADORI, M.R. & DELLA PORTA, G. (1986), Detection of two
TaqI polymorphisms in the VTR region of the human HRASJ
oncogene. Cytogenet. Cell. Genet., 43, 174.
PULCIANI, S., SANTOS, E., LAUVER, A.V., LONG, L.K., AARONSON,
S.A. & BARBACID, M. (1982), Oncogenes in solid human
tumours. Nature, 300, 539.
RAYMOND, Y. & SHORE, G.E. (1979). The precursor for carbamyl
phosphate synthetase is transported to mitochondria via a
cytosolic route. J. Biol. Chem., 254, 9335.
SANTOS, E., MARTIN-ZANCA, D., REDDY, E.P., PIEROTTI, M.A.,
DELLA PORTA, G. & BARBACID, M. (1984). Malignant activation
of a K-ras oncogene in lung carcinoma but not in normal tissue
of the same patient. Science, 223, 661.
SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH, A.
& McGUIRE, W.L. (1987). Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu
oncogene, Science, 235, 177.
SLAMON, D.J., DEKERNION, J.B., VERMA, I.M. & CLINE, M.J. (1984).
Expression of cellular oncogenes in human malignancies. Science,
224, 256.
SOUTHERN, E.M. (1975). Detection of specific sequences among
DNA fragments separated by gel electrophoresis. J. Mol. Biol.,
98, 503.
THEILLET, C., LIDERAU, R., ESCOT, C. & 5 others (1986). Loss of a
c-H-ras-I allele and aggressive human primary breast
carcinomas. Cancer Res., 46, 4776.
WHITTAKER, J.L., WALKER, R.A. & VARLEY, J.M. (1986).
Differential expression of cellular oncogenes in benign and
malignant human breast tissue. Int. J. Cancer, 38, 651.
WHO: Histological Typing of Breast Tumours, Second Edition, 1981.
YOKOTA, J., TSUNETSUGU-YOKOTA, Y., BATFTIFORA, H., LE
FEVRE, C. & CLINE, M.J. (1986), Alterations of myc, myb, and
rasHa proto-oncogenes in cancers are frequent and show clinical
correlations. Science, 231, 261.